affiliation not provided to SSRN
PARP-1 inhibitors, Olaparib, Spirobenzoxazinone, Benzamide, Anti-cancer drug resistance, Cell lines, Docking
Pyrazolo[1, 5-a]pyrimidine, Antitumor, Dual inhibitors, Cyclin dependant kinase CDK2, Apoptosis, Tubulin inhibitor, Colchicine binding site